|
|
- 2018
阿仑膦酸钠对股骨转子间骨折PFNA术后疗效的临床影响
|
Abstract:
摘要 目的 探讨阿仑膦酸钠对老年骨质疏松性股骨转子间骨折PFNA术后疗效的影响.方法 以114例老年骨质疏松性股骨转子间骨折患者作为研究对象.阿仑膦酸钠组在PFNA手术的基础上给予口服阿仑膦酸钠片及碳酸钙D3片,对照组单纯给予PFNA手术及碳酸钙D3片.比较两组患者骨折愈合时间、髋关节Harris评分、术后1年骨矿密度、手术相关并发症及再发骨折情况.结果 阿仑膦酸钠组患者骨折愈合时间为(13.8±1.2)周,对照组为(14.3±1.1)周,两组愈合时间无统计学差异(P=0.204).术后12月,阿仑膦酸钠组患者患髋Harris评分为87.1±5.9,对照组为86.2±5.5,无统计学差异(P=0.514).术后1年阿仑膦酸钠组健髋骨矿密度为0.68±0.07,对照组为0.62±0.08,有统计学差异(P=0.007);阿仑膦酸钠组L2-4椎体骨矿密度高于对照组,有统计学差异(P=0.011).结论 股骨转子间骨折PFNA术后早期使用阿仑膦酸钠不会影响骨折愈合,长期服用阿仑膦酸钠可明显增加患者全身骨密度,但对改善患者患髋功能无帮助.
| [1] | CIPRIANI C, PEPE J, BERTOLDO F, et al.The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study[J]. J Endocrinol Invest, 2018,41(4):431-438. |
| [2] | LEE S H, LEE T J, CHO K J, et al.Subsequent hip fracture in osteoporotic hip fracture patients[J]. Yonsei Med J, 2012,53(5):1005-1009. |
| [3] | PISCITELLI P, AURIEMMA R, NEGLIA C, et al.Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects[J]. Eur Rev Med Pharmacol Sci, 2014,18(24):3788-3796. |
| [4] | BONE H G, HOSKING D, DEVOGELAER J P, et al.Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl [J] Med. 2004, 350(12):1189-1199. |
| [5] | SHARMA A, MAHAJAN A, JOHN B.A comparison of the clinico-radiological outcomes with Proximal Femoral Nail(PFN)and Proximal Femoral Nail Antirotation(PFNA) in fixation of unstable intertrochanteric fractures[J]. J Clin Diagn Res, 2017,11(7):RC05-RC09. |
| [6] | 李煜明, 孙强, 王黎明, 等. 股骨近端带锁髓内钉联合抗骨质疏松药物治疗高龄不稳定型股骨粗隆间骨折的疗效观察[J]. 中华关节外科杂志(电子版), 2014,8(3):395-399. |
| [7] | LI Y M, SUN Q, WANG L M, et al.Effects of proximal femoral nail combining anti-osteoporotic drugs on elderly patients of unstable femoral intertrochanteric fracture[J]. Chinese Journal of Joint Surgery (Electronic Edition), 2014, 8(3):395-399. |
| [8] | MAHARLOUEI N, ATEFI S, NAMAZI H, et al.The incidence of hip fracture in Shiraz, Iran: a promising rate comparing to previous studies[J]. OsteoporosInt, 2017,28(6):1989-1993. |
| [9] | PARK-WYLLIE L Y, MAMDANI M M, JUURLINK D N, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women[J]. JAMA, 2011, 305(8): 783-789. |
| [10] | MEIER R P, PERNEGER T V, STERN R, et al.Increasing occurrence of atypical femoral fractures associated with bisphosphonate use[J]. Arch Intern Med, 2012, 172(12): 930-936. |
| [11] | GONG H S, SONG C H, LEE Y H, et al.Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures[J]. J Bone Joint Surg Am, 2012, 94(19):1729-1936. |
| [12] | GONG H S, SONG C H, LEE Y H, et al.Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures[J]. J Bone Joint Surg Am, 2012, 94(19):1729-1736. |
| [13] | SOUCANYE D L E, BERTANI A, CANDONI P, et al. Proximal femoral nail antirotation (PFN-ATM) fixation of extra-capsular proximal femoral fractures in the elderly: retrospective study in 102 patients[J]. Orthop Traumatol Surg Res, 2012, 98(3):288-295. |
| [14] | SOLOMON D H, HOCHBERG M C, MOGUN H, et al.The relation between bisphosphonate use and non-union of fractures of the humerus in older adults[J]. OsteoporosInt, 2009, 20(6):895-901. |
| [15] | YOO J H, MOON S H, HA Y C, et al.Osteoporotic fracture: 2015 position statement of the korean society for bone and mineral research[J]. J Bone Metab, 2015,22(4):175-181. |
| [16] | IWAMOTO J, UZAWA M.Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures[J]. Clin Rheumatol, 2016,35(1):205-212. |
| [17] | COLON-EMERIC C, NORDSLETTEN L, OLSON S, et al.Association between timing of zoledronic acid infusion and hip fracture healing[J]. Osteoporos Int, 2011, 22(8): 2329-2336. |
